These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35666070)

  • 41. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
    López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
    Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
    Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
    Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
    Ali SO; Dessart C; Parikh R
    Vaccine; 2024 Mar; 42(8):2026-2035. PubMed ID: 38423814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older.
    Ackerson B; Qian L; Sy LS; Bruxvoort K; Wu J; Luo Y; Diaz-Decaro J; Talarico C; Tseng HF
    Vaccine; 2021 Feb; 39(6):926-932. PubMed ID: 33441234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.
    Tavares-Da-Silva F; Co MM; Dessart C; Hervé C; López-Fauqued M; Mahaux O; Van Holle L; Stegmann JU
    Vaccine; 2020 Apr; 38(18):3489-3500. PubMed ID: 31818534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs.
    Kojima S; Iwamoto T; Kobayashi Y; Kato M; Takizawa F; Ida T; Suzuki J; Toda Y; Miyachi K; Iwata A; Furuta S; Ikeda K; Nakajima H
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38388170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Herpes Virus Infections in Kidney Transplant Patients (HINT) - a prospective observational cohort study.
    Hamm SR; Saini SK; Hald A; Vaaben AV; Pedersen NW; Suarez-Zdunek MA; Harboe ZB; Bruunsgaard H; Johansen IS; Larsen CS; Bistrup C; Birn H; Sørensen SS; Hadrup SR; Nielsen SD
    BMC Infect Dis; 2023 Oct; 23(1):687. PubMed ID: 37845608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
    Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
    Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.
    Strezova A; Lal H; Enweonye I; Campora L; Beukelaers P; Segall N; Heineman TC; Schuind AE; Oostvogels L
    Vaccine; 2019 Sep; 37(39):5877-5885. PubMed ID: 31443993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
    Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
    J Virol; 2021 May; 95(12):. PubMed ID: 33762414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine.
    Hurley LP; O'Leary ST; Dooling K; Anderson TC; Crane LA; Cataldi JR; Brtnikova M; Beaty BL; Gorman C; Guo A; Lindley MC; Kempe A
    J Gen Intern Med; 2023 Mar; 38(4):986-993. PubMed ID: 35794307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
    Curran D; Kim JH; Matthews S; Dessart C; Levin MJ; Oostvogels L; Riley ME; Schmader KE; Cunningham AL; McNeil SA; Schuind AE; Andrew MK;
    J Am Geriatr Soc; 2021 Mar; 69(3):744-752. PubMed ID: 33197294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
    Hurley LP; Allison MA; Dooling KL; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen JA; Guo A; Lindley MC; Kempe A
    Vaccine; 2018 Nov; 36(48):7408-7414. PubMed ID: 30420121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Annual incidence rates of herpes zoster among an immunocompetent population in the United States.
    Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
    BMC Infect Dis; 2015 Nov; 15():502. PubMed ID: 26546419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
    Dagnew AF; Rausch D; Hervé C; Zahaf T; Levin MJ; Schuind A;
    Rheumatology (Oxford); 2021 Mar; 60(3):1226-1233. PubMed ID: 32910152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant Zoster Vaccine (Shingrix
    Syed YY
    Drugs Aging; 2018 Dec; 35(12):1031-1040. PubMed ID: 30370455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.
    Vink P; Ramon Torrell JM; Sanchez Fructuoso A; Kim SJ; Kim SI; Zaltzman J; Ortiz F; Campistol Plana JM; Fernandez Rodriguez AM; Rebollo Rodrigo H; Campins Marti M; Perez R; González Roncero FM; Kumar D; Chiang YJ; Doucette K; Pipeleers L; Agüera Morales ML; Rodriguez-Ferrero ML; Secchi A; McNeil SA; Campora L; Di Paolo E; El Idrissi M; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
    Clin Infect Dis; 2020 Jan; 70(2):181-190. PubMed ID: 30843046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.